Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Published online before print August 2, 2006, doi:10.1212/01.wnl.0000229927.12007.37)
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
01.wnl.0000229927.12007.37v1
67/5/872    most recent
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Carpentier, C.
Right arrow Articles by Sanson, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Carpentier, C.
Right arrow Articles by Sanson, M.
Received November 30, 2005
Accepted April 24, 2006

Polymorphism in Sp1 recognition site of the EGF receptor gene promoter and risk of glioblastoma

C. Carpentier MSc, F. Laigle-Donadey MD, Y. Marie MSc, N. Auger MD, A. Benouaich-Amiel MD, J. Lejeune MSc, G. Kaloshi MD, J.-Y. Delattre MD, J. Thillet PhD, and M. Sanson MD, PhD*

From INSERM U711 (C.C., Y.M., N.A., A.B.-A., J.-Y.D., J.T., M.S.), Biologie des Interactions Neurones and Glie, Université Pierre et Marie Curie, Faculté de Médecine, and Groupe Hospitalier Pitié-Salpêtrière, and Service de Neurologie Mazarin (F.L.-D., A.B.-A., J.L., G.K., Y.-Y.D., M.S.), Hôpital de la Salpêtrière, Paris, France.


* To whom correspondence should be addressed. E-mail: marc.sanson{at}psl.ap-hop-paris.fr.

Abstract-- We investigated two polymorphisms of the epidermal growth factor receptor promoter as potential risk factors and prognostic markers for glioblastoma. The -216T allele (which results in a 30% higher activity) was more frequent in the patients compared with the control population (224/376 = 59.6% vs 165/352 = 46.8%; p = 0.0006) corresponding to an odd ratio of 1.67 (1.24; 2.25). A modest difference in median survival was also associated with the TT genotype.




This article has been cited by other articles:


Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
Y.-S. Hong, S. L. Deming, Y.-T. Gao, J.-R. Long, X.-O. Shu, Q. Cai, W. Lu, and W. Zheng
A Two-stage Case-Control Study of EGFR Polymorphisms and Breast Cancer Risk
Cancer Epidemiol. Biomarkers Prev., February 1, 2009; 18(2): 680 - 683.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W.-S. Wang, P.-M. Chen, T.-J. Chiou, J.-H. Liu, J.-K. Lin, T.-C. Lin, H.-S. Wang, and Y. Su
Epidermal Growth Factor Receptor R497K Polymorphism Is a Favorable Prognostic Factor for Patients with Colorectal Carcinoma
Clin. Cancer Res., June 15, 2007; 13(12): 3597 - 3604.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2006 by AAN Enterprises, Inc.